Adlai Nortye is a global clinical-stage biopharmaceutical company that is developing differentiated, innovative immuno-oncology medicines. Adlai Nortye focuses on discovering and developing important new treatments for cancer with a mission to improve patient lives by identifying and developing differentiated innovative medicines that help people live better, live longer.
westvacbiopharmaisfoundedbyacademicianweiyuquanfromwestchinahospitalofsichuanuniversity,togetherwithscientistsfromstatekeylaboratoryofbiotherapy(sklb).itsheadquarterislocatedintheinternationalbio-town,chengdu.theceoofwestvacbiopharmaisprof.weiyuquan,whoistheacademicianofchineseacademyofsciencesaswellasthedirectorofstatekeylaboratoryofbiotherapy.westvaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.ithasattachedgreatimportanceintheresearchanddevelopment(r&d)ofcovid-vaccineespeciallyandbuildingacovid-vaccineproductionplatform.statekeylaboratoryofbiotherapy(sklb)wasestablishedbytheministryofsciencesandtechnologyofchinainandbecameoneofthenationalr&dplatformsfornoveldrugsfoundedbytheministriesofsciencesandtechnologyaswellasthatofhealthofchinain.itisalsosupportedbynationalcollaborativeinnovationprogramandhasbecomethenationalcollaborativeinnovationcenterforbiotherapysince.westchinahospitalofsichuanuniversity,foundedin,isthenationalcenterfordiagnosisandtreatmentofsevereandcriticaldiseasesinwesternchina.itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.relyingonthemedicalresourcesofstatekeylaboratoryofbiotherapyandwestchinamedicalcenter,westvachasadoptedrecombinantproteinmethodologytodevelopthecovid-vaccine.becauseofthesafetyoftheproteinvaccine,itisalsotheonlycovid-vaccineapprovedfortheuseinchildrenoveryearsoldinchina.thevaccinewasapprovedbythenationalmedicalproductsadministrationforclinicaltrialsonaugust,.phasei/iiclinicaltrialshavebeencompleted,andphaseiiiclinicaltrialsarebeingcarriedoutinnepal,kenya,japanandothercountries.thevaccinetargetsthespikeproteinbindingdomain(s-rbd)ofsars-cov-,producingneutralizingantibodiestoblockcovid-infectionofhumancells.theresultwaspublishedonnature,theworld’sfamousscientificjournalonjulyth,.ithasalsobeenthefirstpaperofcovidvaccinepublishedbynaturesincethepandemicoutbreak.thes-rbdgeneofthecovid-virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.suchtechnologyiseasytobemass-producedandbroughttothemarket.westvacbiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.